EP3662287B1 - Systems and methods for real time preparation of a polypeptide sample for anaylsis with mass spectrometry - Google Patents

Systems and methods for real time preparation of a polypeptide sample for anaylsis with mass spectrometry Download PDF

Info

Publication number
EP3662287B1
EP3662287B1 EP18759204.3A EP18759204A EP3662287B1 EP 3662287 B1 EP3662287 B1 EP 3662287B1 EP 18759204 A EP18759204 A EP 18759204A EP 3662287 B1 EP3662287 B1 EP 3662287B1
Authority
EP
European Patent Office
Prior art keywords
polypeptides
port
holding coil
reaction chamber
column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18759204.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3662287A1 (en
Inventor
Chao-Hsiang WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of EP3662287A1 publication Critical patent/EP3662287A1/en
Application granted granted Critical
Publication of EP3662287B1 publication Critical patent/EP3662287B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N2001/002—Devices for supplying or distributing samples to an analysing apparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/38—Diluting, dispersing or mixing samples
    • G01N2001/385—Diluting, dispersing or mixing samples diluting by adsorbing a fraction of the sample

Definitions

  • the present disclosure relates generally to assays and, more specifically, to performing a real-time assay of a sample.
  • sequence listing in electronic format.
  • the sequence listing provided as a file titled, "51800_Seqlisting.txt” created July 31, 2018 and is 263,964 bytes in size.
  • Assays are commonly performed to quantify one or more attributes of an analyte such as a drug, a biochemical substance, or a cell.
  • An example of such an assay is the multi-attribute method (MAM) assay, which can detect and quantify Critical Quality Attributes (CQAs), identified by the Quality Target Product Profile (QTPP), of a sample (Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics.
  • CQAs Critical Quality Attributes
  • QTPP Quality Target Product Profile
  • the MAM assay is a manually-operated process that is performed in, for example, a Large Molecule Release Testing (LMRT) laboratory.
  • MAM is a liquid chromatography (LC) - mass spectrometry (MS) -based peptide mapping method, comprising three steps: (1) sample preparation (such as polypeptide denaturation, reduction, alkylation, and digestion; (2) separation of the digested polypeptides by LC and detection by MS; and (3) analysis of the data for targeted CQAs and detection of new signal ( i.e ., peaks) when compared to a reference standard.
  • sample preparation such as polypeptide denaturation, reduction, alkylation, and digestion
  • MS separation of the digested polypeptides by LC and detection by MS
  • analysis of the data for targeted CQAs and detection of new signal i.e ., peaks
  • Hsieh Y L F et Al Analytical Chemistry, American Chemical Society, vol. 68, no.3, pages 455-462 ,
  • CQAs are chemical, physical, or biological properties that are present within a specific value or range values.
  • physical attributes and modifications of amino acids are important CQAs that are monitored during and after manufacturing, as well as during drug development.
  • MAM detects specific CQAs at the amino acid level.
  • MAM is an important advance in the assessment of CQAs of polypeptide therapeutic molecules during development, manufacturing, and storage (assessing, e.g ., stability), analysis can consume seven to ten days, from sample preparation to final analysis, time that drives costs and delays development and drug release.
  • polypeptide therapeutics are customarily produced by cultured cells expressing the target polypeptide.
  • Such production systems are not easily "put on hold" while MAM analysis of CQAs is pending, resulting in the cells producing the target polypeptide with CQAs that do not meet specifications - a waste of time, materials, and manpower.
  • delays of seven to ten days accumulate during drug development, for example, when optimizing culture conditions, impeding delivery of important and new polypeptide pharmaceuticals to patients.
  • One aspect of the present disclosure provides a method for performing a real-time assay.
  • the method includes the steps of: (a) moving a sample of a product containing polypeptides to a polypeptide-binding column via a first holding coil; (b) binding the polypeptides in the sample to the polypeptide binding column, thereby separating the polypeptides in the sample from a remainder of the sample; (c) moving an elution buffer solution from a buffer source to the polypeptide binding column, via the first holding coil, and through a second holding coil downstream of the polypeptide binding column, thereby eluting polypeptides bound to the polypeptide binding column and moving an elution/polypeptide mixture comprising the elution buffer solution and the eluted polypeptides to the second holding coil; (d) moving the elution/polypeptide mixture from the second holding coil to a reaction chamber; (e) incubating the polypeptides in the elution/
  • Another aspect of the present disclosure provides a method for performing a real-time assay using a closed system including a multi-port valve, a first holding coil upstream of the multi-port valve, a polypeptide binding column fluidly coupled to and downstream of a first port of the multi-port valve, a second holding coil fluidly coupled to and downstream of the polypeptide binding column, a reaction chamber fluidly coupled to and downstream of second and third ports of the multi-port valve, a desalting column fluidly coupled to and downstream of a fourth port of the multi-port valve, and a proteolytic enzyme column downstream of the desalting column.
  • the method includes: (a) moving, via a controller communicatively coupled to the closed system, a sample of a product containing polypeptides to the first holding coil; (b) positioning, via the controller, the multi-port valve in a first position in which the first holding coil is connected to the polypeptide binding column via the first port of the multi-port valve, such that the sample flows to the first column, whereby polypeptides in the sample bind to the polypeptide binding column; (c) when the multi-port valve is in the first position, moving, via the controller, an elution buffer solution from a source of elution buffer solution to the second holding coil via the polypeptide binding column, such that the elution buffer solution elutes substantially all of the polypeptides bound to the polypeptide binding column; (d) moving, via the controller, the multi-port valve to a second position in which the second holding coil is connected to the reaction chamber via the second port of the multi-port valve; (e) when the multi-port valve is in the second position
  • the system includes: a first holding coil fluidly arranged to receive a sample of a product containing polypeptides; a multi-port valve fluidly coupled to and located downstream of the first holding coil; a polypeptide binding column fluidly coupled to the multi-port valve and arranged to receive the sample from the first holding coil via a first port of the multi-port valve, the polypeptide binding column configured to bind the polypeptides from the sample; a buffer source fluidly coupled to the multi-port valve and arranged to supply elution buffer solution to a second holding coil located downstream of the polypeptide binding column, such that the elution buffer solution is adapted to elute substantially all of the polypeptides from the polypeptide binding column; a reaction chamber fluidly coupled to the multi-port valve and arranged downstream of the polypeptide binding column, the reaction chamber adapted to receive a mixture from the polypeptide binding column via a second port of the multi-port valve,
  • the system includes: a multi-port valve; a first holding coil upstream of the multi-port valve; a polypeptide binding column fluidly coupled to and downstream of a first port of the multi-port valve; a second holding coil fluidly coupled to and downstream of the polypeptide binding column; a reaction chamber fluidly coupled to and downstream of second and third ports of the multi-port valve; a desalting column fluidly coupled to and downstream of a fourth port of the multi-port valve; a proteolytic enzyme column downstream of the desalting column; and a controller communicatively coupled to the multi-port valve.
  • the controller includes a memory, a processor, and logic stored on the memory and executable by the processor to: (a) move a sample of a product containing polypeptides to the first holding coil; (b) position the multi-port valve in a first position in which the first holding coil is connected to the polypeptide binding column via the first port of the multi-port valve, such that the sample flows to the first column, whereby polypeptides in the sample bind to the polypeptide binding column; (c) when the multi-port valve is in the first position, move an elution buffer solution from a source of elution buffer solution to the second holding coil via the polypeptide binding column, such that the elution buffer solution elutes substantially all of the polypeptides bound to the polypeptide binding column; (d) move the multi-port valve to a second position in which the second holding coil is connected to the reaction chamber via the second port of the multi-port valve; (e) when the multi-port valve is in the second position, move an elution/pol
  • the present disclosure provides for real-time assays and methods that allows for the monitoring and control of CQAs in real-time, so that the desired final polypeptide therapeutic product can be produced.
  • the disclosed assays and methods can facilitate MAM result turn-around time such that results are available within a few hours ( e.g ., two to three hours) instead of a typical, manually operated, off-line measurement result of seven to ten days.
  • the disclosed assays and methods improve the turn-around time by approximately 54-fold to 120-fold.
  • Such "on-the-fly" (real time) results enable, for example, adjusting production variables to manufacture efficiently (online) products having appropriate CQAs.
  • FIG. 1 illustrates a schematic diagram of a system 100 assembled in accordance with the teachings of the present disclosure.
  • the system 100 which can be located at or in a laboratory (e.g., a Large Molecule Release Testing laboratory) is a closed system for automatically or substantially automatically performing an assay of a sample of a product containing polypeptides, as is described in greater detail below.
  • a laboratory e.g., a Large Molecule Release Testing laboratory
  • the assay can be performed in real-time (or substantially in real-time, such that the entire process can be performed, and the desired result obtained, in a matter of hours ( e.g., 2 to 3 hours), a significant improvement over the 7 to 10 days typically required by the conventionally known, manually-operated MAM assays.
  • the closed nature of the process that utilizes the system 100 maintains sterile conditions.
  • polypeptides can be therapeutic polypeptides, which are discussed further below
  • the system 100 illustrated in FIG. 1 generally includes a multi-port valve 104, a first holding coil 108, a first column 112, a second holding coil 116, a reaction chamber 120, a second column 124, a third column 128, and a controller 132.
  • the system 100 also includes a vessel 136, a pump 140, a first waste chamber 144, a second waste chamber 148, a third waste chamber 152, and an analytical device 156 for analyzing the polypeptides.
  • the system 100 can not include one or more of these components.
  • the system 100 can not include the vessel 136 and/or the analytical device 156.
  • the multi-port valve 104 is generally configured to control fluid communication between the various components of the system 100.
  • the multi-port valve 104 is a twelve satellite port and a central shared port valve.
  • the multi-port valve 104 has a central port 160 and twelve satellite ports 164-175 that are selectively fluidly coupled to the central port 160.
  • the multi-port valve 104 is movable between twelve different positions that fluidly couple the central port 160 with the twelve different satellite ports 164-175, respectively (some of which are not utilized in the operation of the system 100 of FIG. 1 ).
  • the multi-port valve 104 can include more or less satellite ports, can be a different type of valve or can be replaced by one or more different valves (each having one or more ports).
  • the multi-port valve 104 can be replaced by a plurality of single port valves separately connected to and controlled by the controller 132, with each of the single port valves effectively replacing one of the satellite ports 164-175.
  • the vessel 136 is generally configured to hold or store the product containing polypeptides that is to be assayed.
  • the vessel 136 in this version takes the form of a bioreactor that holds or stores the product.
  • the vessel 136 can instead take the form of a cell culture vessel, such as a flask, a plate, etc..
  • the vessel 136 is fluidly coupled to the satellite port 164 of the valve 104 via a conduit 180 of the plumbing, such that the valve 104 can, when desired, obtain a sample of the product contained in the vessel 136 from the vessel 136.
  • the first holding coil 108 is located upstream of the valve 104 and is fluidly coupled to the central port 160 of the valve 104 via a conduit 184 of the plumbing.
  • the first holding coil 108 is thus arranged to receive the sample of the product from the vessel 136, via the valve 104, when the valve 104 is in a first position in which the central port 160 is fluidly coupled to the satellite port 164.
  • the first column 112 is located downstream of the valve 104 and is fluidly coupled to the satellite port 165 of the valve 104 via a conduit 188 of the plumbing.
  • the first column 112 is thus arranged to receive the sample from the first holding coil 108, via the valve 104, when the valve 104 is in a second position in which the central port 160 is fluidly coupled to the satellite port 165.
  • the first column 112 receives the sample, the first column 112 is configured to bind polypeptides from the sample as the sample flows therethrough. In this manner, the first column 112 separates the polypeptides in the sample from a remainder of the sample, which can be passed to the first waste chamber 144 via the second holding coil 116.
  • the first column 112 which can also be referred to herein as a polypeptide-binding column, is selected from the group consisting of a protein A column, a protein G column, a protein A/G column, a protein L column, an amino acid column, an avidin column, a streptavidin column, a carbohydrate bonding column, a carbohydrate column, a glutathione column, a heparin column, a hydrophobic interaction column, an immunoaffinity column, a nucleotide/coenzyme column, a specialty column, and an immobilized-metal affinity chromatography (IMAC) column.
  • IMAC immobilized-metal affinity chromatography
  • protein A columns are useful.
  • Protein G columns can be used to purify human IgGs of subclasses 1-4.
  • Recombinant fusion protein A/G columns can also be used to purify all of these classes of human antibodies, as the fusion protein provides protein A and protein G binding sites.
  • protein A/G fusion proteins can be used to purify human IgG, IgA, IgE, and IgM.
  • protein L columns can be used to purify human IgG, IgM, IgA, IgE and IgD, provided the target antibodies have an appropriate kappa ( ⁇ ) subtype light chain (i.e ., V ⁇ I, V ⁇ III and V ⁇ IV subtypes); protein L columns can also be used to purify Fab and scFv fragments also having the appropriate ⁇ chain subtype, as protein L binds the variable (V) chain of antibodies.
  • ⁇ subtype light chain i.e ., V ⁇ I, V ⁇ III and V ⁇ IV subtypes
  • the pump 140 is located upstream of and fluidly coupled to the first holding coil 108 via a conduit 192 of the plumbing.
  • the pump 140 in this version takes the form of a syringe pump that is fluidly coupled to both a first buffer source 196 and a second buffer source 200.
  • the first buffer source 196 is a elution buffer source that can supply an elution buffer solution 204, e.g., in the case of protein A-bound antibodies, an acidic buffer; or in the case of protein G-bound antibodies, very acidic (pH 3 or less) buffer; one of skill in the art is able to optimize and select appropriate elution buffers for bound antibodies, to the pump 140 (and, ultimately, the first holding coil 108), and the second buffer source 200 is a denaturing buffer (containing a denaturant that disrupts quaternary, tertiary, or secondary polypeptide structure) source that can supply a denaturing reagent 208 to the pump 140 (and, ultimately, the first holding coil 108).
  • the pump 140 can be a different type of pump and/or different pumps 140 can be used for each of the buffer sources 196, 200.
  • the denaturing reagent can be or include a denaturing detergent or a chaotrope.
  • the denaturing detergent is preferably selected from the group consisting of sodium dodecyl sulfate (SDS), sodium cholate, sodium deoxycholate, sodium glycocholate, sodium taurocholate, sodium taurodeoxycholate, N-lauroylsarcosine, lithium dodecyl sulfate, hexadecyltrimethyl ammonium bromide (CTAB) and trimethyl(tetradecyl) ammonium bromide (TTAB). More preferably, the denaturing detergent is SDS.
  • the denaturing reagent is or includes a chaotrope
  • the chaotrope is preferably selected from the group consisting of urea, n-butanol, ethanol, guanidinium chloride, lithium perchlorate, lithium acetate, magnesium chloride, phenol, 2-propanol, and thiourea.
  • the denaturing reagent can be or include a heated fluid that has a temperature suitable for reaching, if not maintaining, a pre-determined temperature (e.g ., about 22 °C to about 120 °C) in the reaction chamber 120 when the denaturing reagent is passed to the reaction chamber 120.
  • a valve 212 is located between the pump 140 and the first and second buffer sources 196, 200 to selectively fluidly couple the pump 140 to only one of the buffer sources 196, 200 at a time. More particularly, the valve 212 is movable between a first position, in which the pump 140 is fluidly coupled to the first buffer source 196 and the pump 140 is fluidly isolated from the second buffer source 200, and a second position, in which the pump 140 is fluidly coupled to the second buffer source 200 and the pump 140 is fluidly isolated from the first buffer source 196. In other words, the pump 140 is selectively fluidly coupled to the first buffer source 196 or the second buffer source 200 depending upon the position of the valve 212.
  • the pump 140 in this version is a syringe pump.
  • the syringe pump 140 is generally configured to obtain a buffer from one of the buffer sources 196, 200 and output that buffer to the first holding coil 108.
  • the pump 140 can obtain ( e.g ., draw in) the elution buffer solution 204 from the first buffer source 196, and, when desired, can output ( e.g ., eject) that elution buffer solution 204 to the first holding coil 108.
  • the pump 140 can obtain ( e.g ., draw in) the denaturing reagent 208 from the second buffer source 200, and, when desired, can output ( e.g. , eject) that denaturing reagent 208 to the first holding coil 108.
  • the second holding coil 116 is located downstream of the valve 104, the first holding coil 108, and the first column 112.
  • the second holding coil 116 is selectively fluidly coupled to the satellite port 166 of the valve 104 via conduits 216, 220 of the plumbing.
  • the second holding coil 116 is also selectively fluidly coupled to the first column 112 via the conduit 220 and a conduit 224.
  • a three-way valve 228 is arranged between the conduits 216, 220, 224 to facilitate the selective coupling in order to produce the desired fluid flow, as is described in greater detail below.
  • the second holding coil 116 is thus arranged to receive the elution buffer solution 204 from the first holding coil 108, via the valve 104 and through the first column 112, when the pump 140 outputs the elution buffer solution 204 in the manner described above, the valve 104 is in the second position in which the central port 160 is fluidly coupled to the satellite port 165. As the elution buffer solution 204 passes through the first column 112, the elution buffer solution 204 elutes substantially all of the polypeptides bound to the first column 112.
  • the three-way valve 228 is operated to connect the conduits 220, 224, thereby fluidly coupling the first column 112 with the second holding coil 116, such that an elution/polypeptide mixture including the elution buffer solution 204 and the eluted polypeptides flows from the first column 112 to the second holding coil 116 via the conduits 220, 224.
  • the reaction chamber 120 is located downstream of the valve 104 and the first column 112, and is fluidly coupled to the satellite port 167 of the valve 104 via conduit 232 of the plumbing.
  • the reaction chamber 120 is partially, if not completely, pre-filled with the denaturing reagent 208 (i.e., filled prior to operation of the system 100) from the second buffer source 200 by using the pump 140 to output the denaturing reagent 208 to the first holding coil 108 and moving the multi-port valve 104 to a fourth position in which the central port 160 is fluidly coupled to the satellite port 167 of the valve 167, thereby facilitating movement of the denaturing reagent 208 from the first holding coil 108 to the reaction chamber 120.
  • the reaction chamber 120 can be partially or completely filled with the denaturing reagent 208 during operation of the system 100 (e.g ., after the second holding coil 116 receives the elution buffer solution 204), partially or completely filled with a denaturing reagent from another buffer source and/or in a different manner, or the reaction chamber 120 may not be filled at all, in which case heat can be applied to the reaction chamber 120 by a heating element 236 connected to the reaction chamber 120.
  • the reaction chamber 120 indirectly receives the elution/polypeptide mixture from the second holding coil 116.
  • the three-way valve 228 is operated to connect the conduits 216, 224, the elution/polypeptide mixture is moved from the second holding coil 116 to the satellite port 166 of the multi-port valve 104 via the conduits 216, 224, the valve 104 is moved to a third position in which the central port 160 is fluidly coupled to the satellite port 166, such that the mixture moves to the first holding coil 108, and the valve 104 is moved to a fourth position in which the central port 160 is fluidly coupled to the satellite port 167 of the valve 104, such that the mixture moves from the first holding coil 108 to the reaction chamber 120.
  • the reaction chamber 120 can directly receive the elution/polypeptide mixture from the second holding coil 116 or can indirectly receive the mixture from the second holding coil 116 utilizing one or more different components and/or in a different order.
  • the reaction chamber 120 can, at the same time or at all times, be heated by the heating element 236 connected to ( e.g ., positioned immediately adjacent, surrounding) the reaction chamber 120 to help facilitate the denaturation process.
  • the heating element 236 can apply heat, preferably heat having a temperature of about 22 °C to about 120 °C and, more preferably, heat having a temperature of about 40 °C, to the reaction chamber 120 to encourage denaturation.
  • the heating element 236 can, for example, take the form of a heating block, a heating coil, an induction heater, a heat pump, a cartridge heater, an electrical resistance wire, a heated fluid, or other element suitable for heating one or more portions of the reaction chamber 120.
  • the process of denaturation can be facilitated.
  • the reaction chamber 120 can not be filled with the denaturing reagent and the denaturation process can be facilitated only by applying heat from the heating element 236.
  • the reaction chamber 120 is configured to receive a reducing reagent that cleaves disulfide bond crosslinks, thereby reducing the denatured polypeptides.
  • the reducing reagent can be selected from the group consisting of dithiothreitol (DTT), glutathione, ⁇ -mercaptoethanol ( ⁇ -ME), and tris(2-carboxyethyl)phosphine (TCEP) and is generally supplied by cooling vessel 240, which can, for example, take the form of a chiller having a temperature of 4 °C.
  • the cooling vessel 240 is located downstream of the valve 104 and has a first chamber 242 that contains the reducing reagent and is fluidly coupled to the satellite port 168 of the valve 104 via conduit 244 of the plumbing.
  • the first chamber 242 supplies the reducing reagent to the first holding coil 108 when the valve 104 is in a fifth position in which the central port 160 is fluidly coupled to the satellite port 168 of the valve 104, and the reducing reagent is then moved from the first holding coil 108 to the reaction chamber 120 when the valve 104 is in (or returns to) the fourth position (in which the central port 160 is fluidly coupled to the satellite port 167).
  • the reducing reagent is indirectly supplied to the reaction chamber 120 via the first holding coil 108.
  • the first chamber 242 can directly supply the reducing reagent to the reaction chamber 120 ( i.e., without moving the reducing reagent to the first holding coil 108).
  • the reaction chamber 120 is configured to receive an alkylating agent that alkylates sulfhydryls in the reaction chamber 120, thereby alkylating the denatured and reduced polypeptides in the reaction chamber 120.
  • the alkylating agent is preferably an alkylating reagent such as indole-3-acetic acid (IAA), though other alkylating agents can be used.
  • the cooling vessel 240 has a second chamber 248 that contains the alkylating agent and is fluidly coupled to the satellite port 169 of the valve 104 via conduit 252 of the plumbing.
  • the second chamber 248 supplies the alkylating agent to the first holding coil 108 when the valve 104 is in a sixth position in which the central port 160 is fluidly coupled to the satellite port 169 of the valve 104, and the alkylating agent is then moved from the first holding coil 108 to the reaction chamber 120 when the valve 104 is in (or returns) to the fourth position.
  • the alkylating agent is indirectly supplied to the reaction chamber 120 via the first holding coil 108.
  • the second chamber 248 can directly supply the alkylating agent to the reaction chamber 120 ( i.e ., without moving the alkylating agent to the first holding coil 108) and/or the alkylating agent can be supplied from a different cooling vessel (e.g ., a cooling vessel separate from the cooling vessel 240).
  • a different cooling vessel e.g ., a cooling vessel separate from the cooling vessel 240.
  • the system 100 further includes a first normally open valve 256 that is fluidly coupled to and located downstream of the reaction chamber 120.
  • the normally open valve 256 has an inlet port 260 that is fluidly connected to an outlet 264 of the reaction chamber 120, a first outlet port 268 that is fluidly connected to the second waste chamber 148, and a second outlet port 272 that is fluidly connected to atmosphere.
  • the normally open valve 256 normally operates in an open, or first, position when the system 100 is in operation and, more particularly, the reaction chamber 120 is receiving and being filled with the elution/polypeptide mixture, the reducing reagent, the alkylating agent, and, in some cases, the denaturing reagent, the valve 256.
  • the inlet port 260 is fluidly coupled to the first outlet port 268 and the inlet port 260 is fluidly isolated from the second outlet port 272, such that when the reaction chamber 120 is filled beyond its fixed volume, any excess contents are directed to the second waste chamber 148.
  • the normally open valve 256 is movable ( e.g ., by applying a current to the valve 256) from the open position to a closed, or second, position when, for example, the reaction chamber 120 is no longer receiving the above-described contents and it is time to clean the reaction chamber 120.
  • the inlet port 260 is fluidly coupled to the second outlet port 272 and the inlet port 260 is fluidly isolated from the first outlet port 268, such that the outlet 264 of the reaction chamber 120 is exposed to the atmosphere. In turn, air can flow into the reaction chamber 120, thereby facilitating the removal of contents from the reaction chamber 120.
  • the second column 124 also referred to herein as the desalting column 124, preferably takes the form of a size exclusion chromatography column that is located downstream of the valve 104 and is fluidly coupled to the satellite port 170 of the valve 104 via a conduit 276 of the plumbing.
  • the second column 124 is thus arranged to receive the denatured, reduced, and alkylated polypeptides, the elution buffer solution 204, the alkylating agent, the reducing reagent, and the denaturing reagent (when one is used) from the reaction chamber 120.
  • the second column 124 indirectly receives these materials from the reaction chamber 120.
  • these materials are moved from the reaction chamber 120 to the first holding coil 108, via the valve 104, when the valve 104 is in (or moved to) the fourth position (in which the central port 160 is fluidly coupled to the satellite port 167), and the valve 104 is moved to a seventh position in which the central port 160 is fluidly coupled to the satellite port 170, such that the materials move from the first holding coil 108 to the second column 124.
  • the second column 124 can directly receive these materials from the reaction chamber 120 or can indirectly receive these materials utilizing one or more different components and/or in a different order.
  • the second column 124 when the second column 124 receives the denatured, reduced, and alkylated polypeptides, the elution buffer solution 204, the alkylating agent, the reducing reagent, and the denaturing reagent (when one is used), the second column 124 is configured to separate the denatured, reduced, and alkylated polypeptides from the elution buffer solution 204, the alkylating agent, the reducing reagent, and the denaturing reagent (when used), which are ultimately moved to the third waste chamber 152.
  • the second column 124 can be referred to herein as the desalting column 124.
  • the second column 124 is configured to buffer exchange the polypeptides into a desired buffer condition that allow the third column 128 to perform the functionality described below.
  • the system 100 further includes a second normally open valve 280 that is fluidly coupled to and located between the second column 124 and the third column 128.
  • the normally open valve 280 has an inlet port 284 that is fluidly connected to an outlet 288 of the second column 124, a first outlet port 292 that is fluidly connected to the third waste chamber 152, and a second outlet port 296 that is fluidly connected to the third column 128.
  • the normally open valve 280 normally operates in an open, or first, position when the system 100 is in operation.
  • the inlet port 284 is fluidly coupled to the first outlet port 292 and the inlet port 284 is fluidly isolated from the second outlet port 296, such that the elution buffer solution 204, the alkylating agent, the reducing reagent, and the denaturing reagent are directed to the third waste chamber 152.
  • the normally open valve 280 is movable ( e.g ., by applying a current to the valve 280) from the open position to a closed, or second, position when it is desired to move the desalted polypeptides from the second column 124 to the third column 128, which is located downstream of the second column 124.
  • the inlet port 284 is fluidly coupled to the second outlet port 296 and the inlet port 284 is fluidly isolated from the first outlet port 292, such that the second column 124 is fluidly coupled to the third column 128, such that the desalted can pass from the second column 124 to the third column 128.
  • the third column 128 includes a proteolytic enzyme (e.g ., an endopeptidase selected from the group consisting of trypsin, chymotrypsin, elastase, thermolysin, pepsin, glutamyl endopeptidase, neprilysin, Lys-C protease, and Staphylococcus aureus V8 protease), such that the third column 128 can be referred to herein as a proteolytic enzyme column.
  • the third column 128 digests the desalted polypeptides obtained from the second column 124.
  • the digested polypeptides can be moved to the analytical device 156, which can, for example, take the form of a liquid chromatography device, a high-performance liquid chromatography device, an ultra high-performance liquid chromatography device, a mass spectrometry device, a glycan analysis device, another analysis device, or a combination thereof.
  • the analytical device 156 is located downstream of the third column 128 and is fluidly coupled to the third column 128 via a conduit 298 of the plumbing.
  • the digested polypeptides can be automatically moved to the analytical device 156 for analysis ( e.g ., for quantification and separation).
  • the analytical device 156 is not be part of the system 100 ( e.g ., not fluidly coupled to the third column 128), in which case the digested polypeptides can be moved to the analytical device 156 in a different manner ( e.g ., manually).
  • the system 100 also includes the controller 132, which in this version is communicatively coupled or connected to various components of the system 100 to monitor and facilitate or direct the above-described operation of the system 100 by transmitting signals (e.g ., control signals, data) to and receiving signals (e.g ., data) from the various components of the system 100.
  • the controller 132 can be located immediately adjacent the other components of the system 100 ( e.g ., in the same environment as the system 100) or can be remotely located from the other components of the system 100.
  • the controller 132 is communicatively coupled or connected to the multi-port valve 104 via a communication network 300, , the pump 140 via a communication network 328, the analytical device 156 via a communication network 332, the heating element 236 via a communication network 340, the first normally open valve 256 via a communication network 344, and the second normally open valve 280 via a communication network 348.
  • the controller 132 can be communicatively coupled or connected to more or less components of the system 100, e.g., the first holding coil 108, the first column 112, the second holding coil 116, the reaction chamber 120, the second column 124, the third column 128, the vessel 136, the three-way valve 228, and/or the cooling vessel 240.
  • the phrases "communicatively coupled” and “connected” are defined to mean directly coupled or connected to or indirectly coupled or connected through one or more intermediate components.
  • Such intermediate components can include hardware and/or software-based components.
  • the networks 300-348 can be wireless networks, wired networks, or combinations of a wired and a wireless network (e.g ., a cellular telephone network and/or 802.1 1x compliant network), and can include a publicly accessible network, such as the Internet, a private network, or a combination thereof.
  • the type and configuration of the networks 300-348 is implementation dependent, and any type of communications networks which facilitate the described communications between the controller 132 and the components of the system 100, available now or later developed, can be used.
  • the controller 132 includes a processor 352, a memory 356, a communications interface 360, and computing logic 364.
  • the processor 352 can be a general processor, a digital signal processor, an application-specific integrated circuit (ASIC), field programmable gate array, graphics processing unit, analog circuit, digital circuit, or any other known or later developed processor.
  • the processor 352 operates pursuant to instructions in the memory 356.
  • the memory 356 can be a volatile memory or a non-volatile memory.
  • the memory 356 can include one or more of a read-only memory (ROM), random-access memory (RAM), a flash memory, an electronic erasable program read-only memory (EEPROM), or other type of memory.
  • the memory 356 can include an optical, magnetic (hard drive), or any other form of data storage device.
  • the communications interface 360 is provided to enable or facilitate electronic communication between the controller 132 and the components of the refrigeration system 100 via the networks 300-348.
  • the communications interface 360 can be or include, for example, one or more universal serial bus (USB) ports, one or more Ethernet ports, and/or one or more other ports or interfaces.
  • USB universal serial bus
  • the electronic communication can occur via any known communications protocol, including, by way of example, USB, RS-232, RS-485, WiFi, Bluetooth, and/or any other suitable communications protocol.
  • the logic 364 generally includes one or more control routines and/or one or more sub-routines embodied as computer-readable instructions stored on the memory 356.
  • the control routines and/or sub-routines can perform PID (proportional-integral-derivative), fuzzy logic, nonlinear, or any other suitable type of control.
  • the processor 352 generally executes the logic 364 to perform actions related to the operation of the system 100.
  • the logic 364 when executed, causes the processor 352 to control components of the system 100, particularly the multi-port valve 104, the pump 140, the heat element 236, the first and second normally open valves 256, 280, and the analytical device 156, such that the system 100 operates in the desired manner discussed herein.
  • the logic 364 can, when executed, cause the processor 352 to (i) move the multi-port valve 104 to or between any of the positions described herein, thereby fluidly coupling various components of the system 100 as described above, (ii) control the pump 140 (e.g ., cause the pump 140 to obtain and output the elution buffer solution 204 or the denaturing reagent 208), (iii) control the heating element 236 (when employed in the system 100) to selectively apply heat to the reaction chamber 120 (and the contents thereof), (iv) control the first normally open valve 256, (v) control the second normally open valve 280, (vi) control the analytical device 156, and perform other desired functionality.
  • control the pump 140 e.g ., cause the pump 140 to obtain and output the elution buffer solution 204 or the denaturing reagent 208
  • control the heating element 236 when employed in the system 100 to selectively apply heat to the reaction chamber 120 (and the contents thereof
  • control the first normally open valve 256 control the second
  • the logic 364 is executable by the processor 352 to position the valve 104 in the first position described above, move the sample of the product from the vessel 136 to the first holding coil 108 via the conduit 180, the port 164, the port 160, position the valve 104 in the second position described above, and move the sample from the first holding coil 108 to and through the polypeptide-binding column 112 via the conduit 184, the ports 160, 164, and the conduit 188.
  • substantially all of the polypeptides in the sample bind to the column 112, such that the polypeptides in the sample are separated from the remainder of the sample, which passes to the first waste chamber 144 via the conduits 220, 224 and the second holding coil 116.
  • the logic 364 is further executable by the processor 352 to cause the pump 140 to obtain the elution buffer solution 204 from the first buffer source 196 and output the elution buffer solution 204 to the first holding coil 108 via the conduit 192.
  • the pump 140 can need to be moved from the second position to the first position (to fluidly couple the pump 140 with the first buffer source 196), but in other cases, the pump 140 can already be in the first position.
  • the logic 364 is executable by the processor 352 to move the elution buffer solution 204 from the first holding coil 108 to and through the first column 112 and to the second holding coil 116, via the conduit 184, the ports 160, 165, and the conduits 188, 220, and 224.
  • the elution buffer solution 204 elutes substantially all of the polypeptides bound to the first column 112, and an elution/polypeptide mixture including the elution buffer solution 204 and the eluted polypeptides flows from the first column 112 to the second holding coil 116.
  • the logic 364 is further executable by the processor 352 to move the valve 104 to the third position described above, move the elution/polypeptide mixture from the second holding coil 116 to the first holding coil 108, via the conduits 224, 216, the ports 166, 160, and the conduit 184, move the valve 104 to the fourth position described above, and move the elution/polypeptide mixture from the first holding coil 108 to the reaction chamber 120, via the conduit 184, the ports 160, 167, and the conduit 232.
  • the polypeptides in the elution/polypeptide mixture are incubated in the reaction chamber 120 with the denaturing reagent 208 and/or in the presence of heat applied by the heating element 236, which thereby denatures the polypeptides.
  • the logic 364 is further executable by the processor 352 to move the valve 104 to the fifth position described above, move the reducing reagent from the first chamber 242 of the cooling vessel 240 to the first holding coil 108 via the conduit 244, the ports 168, 160, and the conduit 184, move the valve 104 back to the fourth position, and move the reducing reagent from the first holding coil 108 to the reaction chamber 120, via the conduit 184, the ports 160, 167, and the conduit 232.
  • the reducing reagent cleaves disulfide bond crosslinks, which thereby reduces the denatured polypeptides in the reaction chamber 120.
  • the logic 364 is further executable by the processor 352 to move the valve 104 to the sixth position described above, move the alkylating agent from the second chamber 248 of the cooling vessel 240 to the first holding coil 108 via the conduit 252, the ports 169, 160, and the conduit 184, move the valve 104 back to the fourth position, and move the alkylating agent from the first holding coil 108 to the reaction chamber 120, via the conduit 184, the ports 160, 167, and the conduit 232.
  • the alkylating agent alkylates sulfhydryls in the reaction chamber 120, which thereby alkylates the denatured and reduced polypeptides in the reaction chamber 120.
  • the logic 364 is further executable by the processor 352 to move the valve 104 to the fourth position (if not already there), move the denatured, reduced, and alkylated polypeptides, the elution buffer solution 204, the alkylating agent, the reducing reagent, and the denaturing reagent (when used) from the reaction chamber 120 to the first holding coil 108, via the conduit 232, the ports 167, 160, and the conduit 184, move the valve 104 to the seventh position described above, and move the denatured, reduced, and alkylated polypeptides, the elution buffer solution 204, the alkylating agent, the reducing reagent, and the denaturing reagent (when used) from the first holding coil 108 to the desalting column 124 via the conduit 184, the ports 160, 170, and the conduit 276.
  • the desalting column 124 separates the denatured, reduced, and alkylated polypeptides from the elution buffer solution 204, the alkylating agent, the reducing reagent, and the denaturing reagent, which are passed or move to the third waste chamber 152.
  • the logic 364 is further executable by the processor 352 to move the normally open valve 256 from its open, first position, wherein the outlet 264 of the chamber 120 is fluidly coupled to the second waste chamber 148 so as to direct contents that will not fit in the reaction chamber 120 (as a result of it being filled beyond its fixed volume) to the second waste chamber 148, to its closed, second position, wherein the outlet 264 is fluidly coupled to atmosphere, such that air can flow into the reaction chamber 120, thereby facilitating the removal of contents from the reaction chamber 120.
  • the normally open valve 256 can return to the open, first position immediately after the reaction chamber 120 has been emptied or can return to the open, first position at a later point in time.
  • the logic 364 is further executable by the processor 352 to move the normally open valve 280 from its open, first position, wherein the inlet port of the valve 280 is fluidly coupled to the third waste chamber 152, to its closed, second position, wherein the inlet port of the valve 280 is fluidly coupled to the proteolytic enzyme column 128.
  • the logic 364 is executable by the processor 352 to move the desalted (or separated) polypeptides from the desalting column 124 to the proteolytic enzyme column 128, which digests the desalted polypeptides.
  • the logic 364 is, at least in this version, further executable by the processor 352 to move the digested polypeptides from the proteolytic enzyme column 128 to the analytical device 156 for analysis of the polypeptides, and to cause the analytical device 156 to perform the desired analysis.
  • the logic 364 can, when executed by the processor 352, cause the analytical device 156 to separate and quantify the polypeptides.
  • the logic 364 can, when executed by the processor 352, cause additional, less, and/or different functionality to be performed.
  • the logic 364, when executed by the processor 352 may not move the digested polypeptides from the column 128 to the analytical device 156 or cause the analytical device 156 to perform the desired analysis.
  • the logic 364 can be executed by the processor 352 in a different order than described herein.
  • the logic 364 can be executed by the processor 352 any number of different times, as the system 100 can be used to perform real-time analyses of multiple samples (from the same product and/or from a different product).
  • FIGS. 3A-3C illustrate the results of an online and real-time MAM assay study designed to monitor the effectiveness of the system 100 in preparing a sample of a product containing a Bispecific T-cell Engager (BiTE ® ) molecule.
  • the study monitored the effectiveness of the system 100 over a production run of 40 days.
  • the study began monitoring and collecting CQA data, such as area percentage for 2 deamidation sites, DS 1 and DS2, and the frequency of a fragmentation, FF, illustrated in FIG. 3A , and MS peak height (expressed as a number of ion counts) for four reference peptides RP1, RP2, RP3, and RP4, illustrated in FIGS.
  • the system 100 capably and effectively performed the intended functionality discussed herein over the entire duration of the 40-day production run, and, as illustrated in FIGS. 3B and 3C , the CQA data collected between day 6 and day 40 was substantially consistent, i.e ., there was no significant change in product quality over time, and the product quality actually increased after day 32, thereby demonstrating the robustness of the system 100 in automatically preparing the sample. Indeed, as illustrated in FIG. 3C , the CQA data collected for RP1, RP2, RP3, and RP4 during that time-period was better than the CQA data obtained during a typical manual MAM assay.
  • Proteins including those that bind to one or more of the following, can be useful in the disclosed devices and methods. These include CD proteins, including CD3, CD4, CD8, CD19, CD20, CD22, CD30, and CD34; including those that interfere with receptor binding.
  • HER receptor family proteins including HER2, HER3, HER4, and the EGF receptor.
  • Cell adhesion molecules for example, LFA-I, MoI, pl50, 95, VLA-4, ICAM-I, VCAM, and alpha v/beta 3 integrin.
  • VEGF vascular endothelial growth factor
  • growth hormone such as vascular endothelial growth factor ("VEGF"), growth hormone, thyroid stimulating hormone, follicle stimulating hormone, luteinizing hormone, growth hormone releasing factor, parathyroid hormone, Mullerian-inhibiting substance, human macrophage inflammatory protein (MIP-I -alpha), erythropoietin (EPO), nerve growth factor, such as NGF-beta, platelet-derived growth factor (PDGF), fibroblast growth factors, including, for instance, aFGF and bFGF, epidermal growth factor (EGF), transforming growth factors (TGF), including, among others, TGF- ⁇ and TGF- ⁇ , including TGF- ⁇ 1, TGF- ⁇ 2, TGF- ⁇ 3, TGF- ⁇ 4, or TGF- ⁇ 5, insulin-like growth factors-I and -II (IGF-I and IGF-II), des(1-3)-IGF-I (brain IGF-I), and osteoinductive factors.
  • Insulins and insulin-related proteins including insulin, insulin A-chain, insulin B-chain, proinsulin, and insulin-like growth factor binding proteins.
  • Coagulation and coagulation-related proteins such as, among others, factor VIII, tissue factor, von Willebrands factor, protein C, alpha-1-antitrypsin, plasminogen activators, such as urokinase and tissue plasminogen activator ("t-PA"), bombazine, thrombin, and thrombopoietin; (vii) other blood and serum proteins, including but not limited to albumin, IgE, and blood group antigens.
  • Colony stimulating factors and receptors thereof including the following, among others, M-CSF, GM-CSF, and G-CSF, and receptors thereof, such as CSF-1 receptor (c-fms).
  • Receptors and receptor-associated proteins including, for example, flk2/flt3 receptor, obesity (OB) receptor, LDL receptor, growth hormone receptors, thrombopoietin receptors ("TPO-R,” "c-mpl”), glucagon receptors, interleukin receptors, interferon receptors, T-cell receptors, stem cell factor receptors, such as c-Kit, and other receptors.
  • Receptor ligands including, for example, OX40L, the ligand for the OX40 receptor.
  • Neurotrophic factors including bone-derived neurotrophic factor (BDNF) and neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6).
  • Interleukins and interleukin receptors including IL-I to IL-33 and IL-I to IL-33 receptors, such as the IL-8 receptor, among others.
  • Viral antigens including an AIDS envelope viral antigen.
  • Lipoproteins Lipoproteins, calcitonin, glucagon, atrial natriuretic factor, lung surfactant, tumor necrosis factor-alpha and -beta, enkephalinase, RANTES (regulated on activation normally T-cell expressed and secreted), mouse gonadotropin-associated peptide, DNAse, inhibin, and activin. Integrin, protein A or D, rheumatoid factors, immunotoxins, bone morphogenetic protein (BMP), superoxide dismutase, surface membrane proteins, decay accelerating factor (DAF), AIDS envelope, transport proteins, homing receptors, addressins, regulatory proteins, immunoadhesins, antibodies.
  • BMP bone morphogenetic protein
  • DAF decay accelerating factor
  • TALL proteins including TALL-I
  • amyloid proteins including but not limited to amyloid-beta proteins, thymic stromal lymphopoietins ("TSLP"), RANK ligand ("OPGL”), c-kit
  • TNF receptors including TNF Receptor Type 1, TRAIL-R2, angiopoietins, and biologically active fragments or analogs or variants of any of the foregoing.
  • Exemplary polypeptides and antibodies include Activase ® (Alteplase); alirocumab, Aranesp ® (Darbepoetin-alfa), Epogen ® (Epoetin alfa, or erythropoietin); Avonex ® (Interferon ⁇ -Ia); Bexxar ® (Tositumomab); Betaseron ® (Interferon- ⁇ ); bococizumab (anti-PCSK9 monoclonal antibody designated as L1L3, see US8080243 ); Campath ® (Alemtuzumab); Dynepo ® (Epoetin delta); Velcade ® (bortezomib); MLN0002 (anti- ⁇ 4 ⁇ 7 mAb); MLN1202 (anti-CCR2 chemokine receptor mAb); Enbrel ® (etanercept); Eprex ® (Epoet
  • anthracis Protective Antigen mAb ABthraxTM; Vectibix ® (Panitumumab); Xolair ® (Omalizumab), ETI211 (anti-MRSA mAb), IL-I Trap (the Fc portion of human IgG1 and the extracellular domains of both IL-I receptor components (the Type I receptor and receptor accessory protein)), VEGF Trap (Ig domains of VEGFRl fused to IgG1 Fc), Zenapax ® (Daclizumab); Zenapax ® (Daclizumab), Zevalin ® (Ibritumomab tiuxetan), Zetia (ezetimibe), Atacicept (TACI-Ig), anti- ⁇ 4 ⁇ 7 mAb (vedolizumab); galiximab (anti-CD80 monoclonal antibody), anti-CD23 mAb (lumiliximab); BR2-Fc (huBR3
  • antibodies suitable for the methods and pharmaceutical formulations include the antibodies shown in Table 1.
  • suitable antibodies include infliximab, bevacizumab, cetuximab, ranibizumab, palivizumab, abagovomab, abciximab, actoxumab, adalimumab, afelimomab, afutuzumab, alacizumab, alacizumab pegol, ald518, alemtuzumab, alirocumab, altumomab, amatuximab, anatumomab mafenatox, anrukinzumab, apolizumab, arcitumomab, aselizumab, altinumab, atlizumab, atorolimiumab, tocilizumab, bapineuzumab, basiliximab, bavituximab, bectumomab, be
  • Antibodies also include adalimumab, bevacizumab, blinatumomab, cetuximab, conatumumab, denosumab, eculizumab, erenumab, evolocumab, infliximab, natalizumab, panitumumab, rilotumumab, rituximab, romosozumab, tezepelumab, and trastuzumab, and antibodies selected from Table 1. Table 1 Examples of therapeutic antibodies Target (informal name) Conc.
  • the devices, systems, and methods described herein facilitate the performance of an assay of a sample substantially in real-time.
  • the assay can be performed, and the desired result obtained, much more quickly than allowed by conventional processes.
  • the devices, systems, and methods described herein allow the process of preparing the online, real-time assay using the system 100 to be easily monitored, which can in turn mitigate risk and extend a production run of the product.
  • this process can be monitored by determining, e.g., using a controller such as the controller 132 and/or manually by an operator of the system 100, whether conditions in the system 100 are optimal, i.e., whether they satisfy a pre-determined performance threshold. As illustrated in FIGS.
  • 3B and 3C for example, MS Peak Height, expressed in ion counts, for the four reference peptides RP1, RP2, RP3, and RP4 can be obtained and compared against historical values for those reference peptides during the method qualification to determine whether conditions in the system 100 are optimal (and they are), such that the production run can be commenced, continued, or extended. However, when it is determined that the conditions in the system 100 are not optimal, at least one cell culture component can be adjusted until the conditions in the closed system are optimal.
  • cell culture components examples include, but are not limited to: pH, pressure, temperature, media flow (e.g ., media flow rate, media feed rate), media content (including amino acids, nutrients, sugars, buffer), gassing strategy (e.g., mix of oxygen and carbon dioxide, gas rate), agitation ( e.g ., agitation rate), additives (e.g., metal additives, sugar additives), additive (e.g ., anti-foam) feed rate, and perfusion rate.
  • gassing strategy e.g., mix of oxygen and carbon dioxide, gas rate
  • agitation e.g ., agitation rate
  • additives e.g., metal additives, sugar additives
  • additive e.g ., anti-foam feed rate
  • perfusion rate perfusion rate.
  • only one cell culture component may need to be adjusted so that the conditions in the closed system are optimal, while in other cases, multiple cell culture components may need to be adjusted.
  • the controller and/or the operator of the system 100
  • the devices, systems, and methods described herein also mitigate risk involved in the continued operation of the system 100 when conditions are not optimal or when it is otherwise undesirable to continue operation of the system 100.
  • risk can be mitigated by determining (e.g ., calculating or obtaining) process parameter and product quality data, e.g ., pH, temperature, oxygen dissolution, cell viability, cell density, titer, aggregation, charge variant, glycosylation, etc., associated with the current operation of the system 100, determining whether the process parameter and product quality data satisfy a pre-determined risk threshold (determined before operation of the system 100 by a controller such as the controller 132 and/or responsive to input from the operator of the system 100), and then determining whether to continue, cease, or adjust operation of the system 100 based upon whether the process parameter and product quality data satisfy the pre-determined risk threshold.
  • a pre-determined risk threshold determined before operation of the system 100 by a controller such as the controller 132 and/or responsive to input from the operator of the system 100
  • the pre-determined risk threshold may, for example, be determined by looking at (1) applying available process parameter data and product quality data to calculate average historical multi-variate (MV) data associated with the previous operation of the system 100 or some other similar system, and then (2) establishing the calculated average historical MV data as the threshold (the threshold may be calculated average historical MV data itself or some value or set of values based on the calculated average historical MV data.
  • the pre-determined risk threshold may represent an acceptable deviation (e.g., three standard deviations) from the calculated average historical MV data.
  • the pre-determined risk threshold may be determined based upon input from the operator of the system 100.
  • the system 100 may be shut down when the process parameter and product quality data associated with the current operation of the system 100 do not satisfy ( e.g ., exceed) the pre-determined risk threshold. In other cases, however, the system 100 may be adjusted when the process parameter and product quality data associated with the current operation of the system 100 do not satisfy ( e.g ., exceed) the pre-determined risk threshold or even when the process parameter and product quality data satisfy but are close to the pre-determined risk threshold.
  • the Applicant has discovered that the devices, systems, and methods described herein also allow production runs using the system 100 to be extended. Conventional processes typically allow for 32 to 40-day production runs, at most. However, the Applicant has found that the devices, systems, and methods described herein allow for 50-80 if not 100 population doublings, i.e ., approximately 50-80 if not 100 day production runs. Thus, more product can be obtained, all while operation of the system 100 is monitored to ensure that the product satisfies quality objectives and risk is mitigated.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP18759204.3A 2017-08-01 2018-08-01 Systems and methods for real time preparation of a polypeptide sample for anaylsis with mass spectrometry Active EP3662287B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762539803P 2017-08-01 2017-08-01
PCT/US2018/044887 WO2019028187A1 (en) 2017-08-01 2018-08-01 SYSTEMS AND METHODS FOR REAL-TIME PREPARATION OF A POLYPEPTIDE SAMPLE FOR MASS SPECTROMETRY ANALYSIS

Publications (2)

Publication Number Publication Date
EP3662287A1 EP3662287A1 (en) 2020-06-10
EP3662287B1 true EP3662287B1 (en) 2024-02-28

Family

ID=63350600

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18759204.3A Active EP3662287B1 (en) 2017-08-01 2018-08-01 Systems and methods for real time preparation of a polypeptide sample for anaylsis with mass spectrometry

Country Status (15)

Country Link
US (1) US12104995B2 (zh)
EP (1) EP3662287B1 (zh)
JP (1) JP7237022B2 (zh)
KR (1) KR102560646B1 (zh)
CN (1) CN110869768B (zh)
AU (1) AU2018309027A1 (zh)
BR (1) BR112020001885A2 (zh)
CA (1) CA3071676A1 (zh)
CL (1) CL2020000248A1 (zh)
EA (1) EA202090399A1 (zh)
ES (1) ES2978396T3 (zh)
IL (1) IL271499B1 (zh)
MA (1) MA49757A (zh)
SG (1) SG11202000727SA (zh)
WO (1) WO2019028187A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3071636A1 (en) 2017-08-01 2019-02-07 Amgen Inc. Systems and methods for performing a real-time glycan assay of a sample
IL271499B1 (en) 2017-08-01 2024-08-01 Amgen Inc Systems and methods for real-time polypeptide sample preparation for mass spectrometry analysis
EP4397977A3 (en) * 2019-02-14 2024-09-11 Amgen Inc. Systems and methods for preparing a sample and performing a real-time assay of the sample
FR3096459B1 (fr) * 2019-05-20 2024-03-08 Ct Hospitalier Universitaire Montpellier Procédé de préparation d’un échantillon peptidique
WO2022226339A1 (en) * 2021-04-23 2022-10-27 Amgen Inc. Anti-tslp antibody compositions and uses thereof
EP4326762A2 (en) * 2021-04-23 2024-02-28 Amgen Inc. Modified anti-tslp antibodies
AU2023226148A1 (en) * 2022-02-24 2024-08-22 Venn Biosciences Corporation Sample preparation for glycoproteomic analysis that includes diagnosis of disease
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661349B2 (en) * 1991-09-30 1995-07-20 Perseptive Biosystems, Inc. Protein chromatography system
CA2146177C (en) * 1995-04-03 2000-09-05 Adrian P. Wade Intelligent flow analysis network
EP1300679A3 (en) * 1995-06-26 2004-04-14 Perseptive Biosystems, Inc. Molecular selection and analysis
DE69627333T2 (de) * 1995-06-26 2004-02-12 PerSeptive Biosystems, Inc., Framingham Automatisierte, kontinuierliche mehrdimensionale hochgeschwindigkeitsmolekularselektion und -analyse
JPH1194816A (ja) * 1997-09-22 1999-04-09 Mitsubishi Heavy Ind Ltd 高速液体クロマトグラフ分析装置
US20080153711A1 (en) * 2000-02-08 2008-06-26 Regents Of The University Of Michigan Protein microarray system
US6887429B1 (en) * 2001-01-26 2005-05-03 Global Fia Apparatus and method for automated medical diagnostic tests
EA014802B1 (ru) 2001-08-23 2011-02-28 Генмаб А/С АНТИТЕЛА К ИНТЕРЛЕЙКИНУ 15 (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, ИММУНОКОНЪЮГАТ НА ИХ ОСНОВЕ, ГИБРИДОМА, ТРАНСФЕКТОМА, ТРАНСГЕННОЕ ЖИВОТНОЕ, ЭКСПРЕССИОННЫЙ ВЕКТОР (ВАРИАНТЫ) И НУКЛЕИНОВАЯ КИСЛОТА ДЛЯ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ (ВАРИАНТЫ) И СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ ИЛ-15, СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОДУКЦИИ TNF-α И СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОЛИФЕРАЦИИ КЛЕТОК
US20040053356A1 (en) * 2001-12-28 2004-03-18 Mds Proteomics Inc. Enzyme/chemical reactor based protein processing method for proteomics analysis by mass spectrometry
US20040009567A1 (en) * 2001-12-28 2004-01-15 Mds Proteomics Inc. Enzyme/chemical reactor based protein processing method for proteomics analysis by mass spectrometry
US8669116B2 (en) * 2002-03-11 2014-03-11 President And Fellows Of Harvard College Detection and quantification of modified proteins
US20040009597A1 (en) 2002-07-03 2004-01-15 Isis Pharmaceuticals Inc. Antisense modulation of PTPRK expression
WO2004063719A2 (en) * 2003-01-13 2004-07-29 The Regents Of The University Of Michigan Method to form a protein microarray system
WO2004081535A2 (en) * 2003-03-12 2004-09-23 Bionova Corporation The establishment of proteome structure profile databases and their uses
WO2005000226A2 (en) * 2003-06-06 2005-01-06 Diversa Corporation Mixed bed multi-dimensional chromatography systems and methods of making and using them
EP1841455A1 (en) 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2008155365A1 (en) 2007-06-20 2008-12-24 Irm Llc Methods and compositions for treating allergic diseases
KR20100038235A (ko) * 2007-08-31 2010-04-13 에프. 호프만-라 로슈 아게 글리코실화 프로파일 분석
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JP2013507603A (ja) * 2009-10-09 2013-03-04 シムフォゲン・アクティーゼルスカブ 署名ペプチドおよび質量分析による混合物中の個々の組換えタンパク質の多重定量化
US9453845B2 (en) * 2010-02-01 2016-09-27 Cell Signaling Technology, Inc. Mass spectroscopy analysis of mutant polypeptides in biological samples
WO2011116028A1 (en) * 2010-03-15 2011-09-22 Anderson Forschung Group, Inc. Improved mass spectrometric assays for peptides
WO2012037407A1 (en) 2010-09-17 2012-03-22 Prozyme, Inc. Isolation and deglycosylation of glycoproteins
US20140030732A1 (en) 2012-07-25 2014-01-30 Agilent Technologies, Inc. Microfluidic hplc-chip for glycopeptide analysis with integrated hilic enrichment
US9322014B1 (en) * 2012-11-28 2016-04-26 Sandia Corporation Multiplexed microfluidic approach for nucleic acid enrichment
US9927399B2 (en) * 2013-11-12 2018-03-27 Nichiei Industry Co., Ltd. Capillary device for separation and analysis, microfluidic chip for separation and analysis, analysis method for proteins or peptides, electrophoresis instrument, and microfluidic chip electrophoresis instrument for separation and analysis
US9683707B2 (en) * 2014-08-19 2017-06-20 Elemental Scientific, Inc. Ultraclean autosampler with syringe delivery for mass spectrometry
WO2016108135A1 (en) * 2014-12-31 2016-07-07 Dh Technologies Development Pte. Ltd. Methods for protein and peptide reduction
IL271499B1 (en) 2017-08-01 2024-08-01 Amgen Inc Systems and methods for real-time polypeptide sample preparation for mass spectrometry analysis
EP4397977A3 (en) 2019-02-14 2024-09-11 Amgen Inc. Systems and methods for preparing a sample and performing a real-time assay of the sample

Also Published As

Publication number Publication date
KR20200035093A (ko) 2020-04-01
KR102560646B1 (ko) 2023-07-27
CA3071676A1 (en) 2019-02-07
JP7237022B2 (ja) 2023-03-10
CL2020000248A1 (es) 2020-08-14
CN110869768A (zh) 2020-03-06
US20200355582A1 (en) 2020-11-12
BR112020001885A2 (pt) 2020-08-04
WO2019028187A1 (en) 2019-02-07
MA49757A (fr) 2020-06-10
CN110869768B (zh) 2023-11-21
IL271499A (en) 2020-02-27
JP2020530103A (ja) 2020-10-15
EP3662287A1 (en) 2020-06-10
IL271499B1 (en) 2024-08-01
EA202090399A1 (ru) 2020-05-20
US12104995B2 (en) 2024-10-01
ES2978396T3 (es) 2024-09-11
SG11202000727SA (en) 2020-02-27
AU2018309027A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
EP3662287B1 (en) Systems and methods for real time preparation of a polypeptide sample for anaylsis with mass spectrometry
EP3662288B1 (en) Systems and methods for performing a real-time glycan assay of a sample
EP3924083B1 (en) Systems and methods for preparing a sample and performing a real-time assay of the sample
US20220404370A1 (en) Methods of protein clips recovery
US12000775B2 (en) System suitability method for use with protein concentration determination by slope
EA043377B1 (ru) Системы и способы для подготовки в режиме реального времени образца полипептида для анализа с помощью масс-спектрометрии
EA043925B1 (ru) Системы и способы для выполнения анализа гликанов в образце в режиме реального времени

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230926

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240104

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018065875

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240528

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240528

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240528

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240628

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240529

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240628

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1661702

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240628

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240723

Year of fee payment: 7

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2978396

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240911

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240723

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240723

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240723

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240902

Year of fee payment: 7

Ref country code: CH

Payment date: 20240901

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240723

Year of fee payment: 7